Alignment Healthcare Third Quarter 2026 Earnings Call - ALIGNMENT HEALTHCARE INC

Explicit Guidance:

• Q4 2026: Revenue of at least $1.32 billion; Health plan membership of at least 305,000; Adjusted gross profit of at least $104 million (implying an MBR of 92.1%); Adjusted EBITDA of at least negative $28 million.
• Full Year 2026: Revenue of at least $5.25 billion; Adjusted gross profit of at least $575 million; Adjusted EBITDA of at least $100 million.
• Assumptions for Q4/FY2026: Guidance assumes continued elevated medical claims trends observed in Q3 (peaking in July), specifically higher provider appeals/disputes and costs in skilled nursing and catastrophic cases. It includes full burdening of current operational initiatives and assumes no immediate benefit from payment integrity or clinical investments currently underway. Part D seasonality is assumed to drive further margin pressure.

Business-Segment Outlook:

• 2027 Growth Target: Management expects membership growth of at least 20% for 2027, driven by favorable AEP results and bid recalibration.
• Product Mix & Strategy: Shift toward more balanced growth across traditional HMO products; continued selective growth in C-SNP products where margins remain robust; potential de-emphasis of specific products/markets where bid assumptions were inconsistent with current trends.
• California HMO: A 3.5-star rating for payment year 2028 is a key focus; management asserts this has not negatively impacted broker relationships or early AEP sales confidence.
• Clinical Model: Continued investment in clinical operations to reduce outcome variability; focus on closing HEDIS gap closures (Part B) and addressing "H" (Health Outcomes Survey) and "H" (Hospital) measure misses.

Market and Competitive Outlook:

• Competition: Anticipated intensification in the D-SNP/C-SNP landscape in 2027, particularly as Medicaid (MA) benchmark increases may not fully offset cost pressures in a new industry environment.
• Provider Dynamics: Strategic shift to "de-delegate" inpatient utilization management (UM) from IPAs (currently ~80% complete) and move toward greater control over pre-service (outpatient/professional) UM to improve margin visibility.
• Network Expansion: New partnerships announced including Hoag Memorial (Orange County) and Estrana (LA expansion); entering San Antonio and Charlotte in 2027.
• Geographic Expansion: Diligent work to add a couple of new states in 2028; 2027 expansion limited to San Antonio and Charlotte to ensure operational stability.

Macro / Industry Outlook:

• Cost Trends: Medical cost trends are expected to normalize in 2027 following the volatility caused by the FACETS claims system migration in mid-2026; current trends are assumed to persist through Q4 2026.
• Regulatory/Star Ratings: Management views Star ratings as a "cultural requirement" rather than a functional department; acknowledges that higher industry cut points contributed to the California shortfall.
• System Transformation: The migration to the FACETS claims adjudication system (live July 2026) is viewed as a necessary long-term investment to improve auto-adjudication, payment speed, and payment integrity against provider AI initiatives; volatility is expected to subside as the system stabilizes.

Strategic Initiatives:

• Payment Integrity: Rapid deployment of industry-standard prepay claims edits and rigorous post-pay reviews to address aggressive provider appeals; expected to become a primary driver of margin improvement in 2027.
• Utilization Management: Increased internal control over inpatient utilization and a strategic pivot to manage pre-service costs (outpatient/professional) more directly, particularly outside California.
• Investments: Double-digit millions in incremental clinical and SG&A investments already running in 2026 to support 2027 growth; no additional specific investment amounts announced beyond current run-rate.
• Risk Adjustment: Commitment to a conservative approach to coding, with identified opportunities to improve risk adjustment capture efficiency in 2027.

Risks and Headwinds to Outlook:

• Cost Volatility: Continued elevated trends in provider appeals, disputes, skilled nursing length of stay, and catastrophic cases for the remainder of 2026.
• Star Rating Performance: The California 3.5-star rating poses a funding headwind for payment year 2028 (based on 2026 dates of service); failure to remediate "H" and "H" measures could impact 2028 margins.
• System Transition: Residual volatility from the FACETS migration could impact claims processing accuracy if not fully stabilized.
• Competition: Potential margin compression due to intense competition in the D-SNP space and limited revenue benchmark increases in 2027.
• Caveats: Guidance is explicitly conservative, excluding any upside from initiatives currently in progress (payment integrity, clinical model optimization) and assuming no return on investments until they stabilize.

Management Tone on the Future:

• Confidence Level: Prudent and disciplined; management expresses strong confidence in delivering the revised 2026 guidance and a solid, profitable growth path for 2027.
• Forward Outlook: Optimistic about the long-term structural improvements (FACETS, payment integrity, clinical rigor) despite short-term headwinds.
• Reset Narrative: Characterizes the current period as a "transformative phase" and a necessary "reset" to ensure reliability for future growth; emphasizes "getting through this" to return to a "beat and raise" cadence.
• Tone on Guidance: Explicitly advises analysts against annualizing Q4 MLR for 2027 projections, citing the prudence embedded in the current guidance versus expected run-rate benefits in 2027.

Miscellaneous:

• Reserves: Reserve position is described as "well-positioned" and "very good" at 99% run-out for 2025 dates of service; Q2/Q3 reserve actions were prudent to bolster coverage during system transition volatility.
• Leadership & Culture: CEO and leadership team are personally committed to resolving Star rating issues; culture of "serving the senior" is being re-emphasized across the organization.
• Liquidity: Strong balance sheet with $743 million in cash/cash equivalents/short-term investments and a funded leverage ratio of 2.4x trailing 12-month EBITDA.